Cart
sales@molnova.com
TAK-931
CAS No. 1330782-76-7
TAK-931( Simurosertib | TAK931 )
Catalog No. M11316 CAS No. 1330782-76-7
TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 160 | In Stock |
|
| 5MG | 154 | In Stock |
|
| 10MG | 215 | In Stock |
|
| 25MG | 399 | In Stock |
|
| 50MG | 551 | In Stock |
|
| 100MG | 762 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAK-931
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
-
DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM; prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis, demonstrates antiproliferative activity with cancer cell lines and tumor growth inhibition (TGI) in murine ectopic xenograft models. Colon Cancer,Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsSimurosertib | TAK931
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationColon Cancer
Chemical Information
-
CAS Number1330782-76-7
-
Formula Weight341.433
-
Molecular FormulaC17H19N5OS
-
Purity>98% (HPLC)
-
SolubilityDMSO : 75 mg/mL 219.66 mM
-
SMILESO=C1C2=C(C=C(C3=CNN=C3C)S2)N=C([C@H]4N(CC5)CCC5C4)N1
-
Chemical NameThieno[3,2-d]pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo[2.2.2]oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Charles Locuson, et al. Abstract 5041: Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor. AACR.
2. Kenichi Iwai, et al. Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931. AACR.
molnova catalog
related products
-
AZD-4573
AZD-4573 (AZD4573) is a potent and selective inhibitor of CDK9, with fast-off binding kinetics and high selectivity versus other kinases, including other CDK family kinases.
-
CLK1/2-IN-3
CLK1/2-IN-3 (Cpd-3) is a potent and selective CLK1 and CLK2 inhibitor with antiproliferative activity and inhibits the activities of CLK1, CLK2, SRPK1, SRPK2, and SRPK3.CLK1/2-IN-3 induces nuclear speckle enlargement.
-
Roniciclib
A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.
